Lukas Greilich

Mr. Greilich has significant experience in capital markets transactions, representing issuers, shareholders and underwriters in connection with initial public offerings, capital increases, rights offerings, block trades, and offerings of convertible and hybrid capital instruments. His practice also includes capital markets-related regulatory advice. In recognition of his work, Mr. Greilich has been repeatedly named one of Best Lawyers’ Ones To Watch (including in its 2025 edition) and most recently honored as a Rising Star in Capital Markets by IFLR1000. His recent significant representations include advising:

Capital Markets (Equity)

• Euronext Brussels and Euronext Amsterdam-listed ONWARD Medical, a leading developer of spinal cord injury therapies, in:
  • a €50 million cash capital increase and cornerstone investment by Ottobock SE & Co. KGaA
  • a €52.5 million debt financing from U.S. lender Runway Growth Finance
• HSBC, Morgan Stanley and UBS (acting as joint global coordinators for a banking syndicate) as international underwriters’ counsel in connection with the 775 million Swiss franc rights offering of ams OSRAM
• FINN, a leading car subscription platform, in its US$110 million Series B financing round led by Korelya Capital, including both new and existing investors, with an implied company value of more than US$500 million
• Berenberg Capital Markets LLC and Craig-Hallum Capital Group LLC as underwriters in the proposed IPO of common shares and listing on Nasdaq of Sono Group N.V.
• Morgan Stanley and UBS as joint global coordinators and joint bookrunners in connection with a capital increase of Bachem Holding AG
• the joint bookrunners, including Deutsche Bank and J.P. Morgan, in the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of ABOUT YOU Holding AG
• Bank of America, Morgan Stanley and UBS in the €2.3 billion initial public offering of ordinary shares of Vantage Towers AG on the Frankfurt Stock Exchange
• Jefferies and BofA Securities as joint global coordinators and joint bookrunners in connection with capital increases of Zur Rose Group AG

Capital Markets (Equity-Linked/Debt)

• banks in the €200 million senior notes offering of ams OSRAM
• ONWARD Medical in connection with a loan agreement
• Deutsche Bank, HSBC, UBS, COMMERZBANK and UniCredit in connection with the issuance of senior unsecured notes in the aggregate principal amount of €1 billion by ams OSRAM
• AGRAVIS Raiffeisen AG on multiple issuance of participation rights
• UBS and HSBC as global coordinators in connection with the €650 million and US$400 million senior notes offering of ams AG and the subsequent tap offering of €200 million and US$50 million

Mergers and Acquisitions

• the management and supervisory boards of Fresenius in the company’s exit from the Austrian and international businesses of VAMED AG
• phenox and its shareholders, including health care private equity investor SHS, on the sale of phenox to Wallaby Medical for a total consideration of €500 million including milestone payments
• Armira and Boxine in Boxine’s €1 billion business combination with 468 SPAC I SE, one of the first de-SPAC transactions in the market involving a German-listed blanc cheque company
• SIGNA Sports United GmbH in connection with its US$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group

Mr. Greilich’s representations prior to joining Skadden include advising:

• Goldman Sachs International, Morgan Stanley and Berenberg on the IPO of Global Fashion Group S.A.
• Siemens Healthineers AG on its IPO on the Frankfurt Stock Exchange
• Berenberg and ODDO BHF on the IPO of Dermapharm Holding SE on the Frankfurt Stock Exchange
• Deutsche Bank, J.P. Morgan, Morgan Stanley, Berenberg, BNP Paribas and Rabobank on the IPO of HelloFresh SE on the Frankfurt Stock Exchange
• ZF Friedrichshafen AG on the sale of a stake in Haldex A/B by way of an accelerated book building offering to institutional investors